By Drug Target Review2024-09-06T12:00:53
The mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-18T14:47:08Z
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2023-03-07T10:55:58
Sponsored by Agilent
2024-01-26T13:22:42
Sponsored by bit.bio
2023-03-08T16:29:20
Sponsored by Bio-Techne
2023-07-11T16:13:06
Sponsored by Agilent
Site powered by Webvision Cloud